CD274 and endometrial cancer: In this context the DUO-E trial could demonstrate that the combination of the anti-PD-L1 antibody Durvalumab to standard first-line chemotherapy, followed by Durvalumab and the PARP inhibitor Olaparib, improved outcomes in newly diagnosed advanced or recurrent endometrial cancer especially in the PD-L1–positive subgroup (TAP > 1%) [19].